Modular Medical, Inc. (MODD): Nasdaq/NYSE listing notice — Modular Medical receives Nasdaq minimum bid price deficiency notice; 180-day cure period

Modular Medical, Inc.

Nasdaq notified Company of bid price deficiency: closing bid below $1.00 for 30 consecutive business days ending June 27, 2025.
Company has 180 calendar days (until Dec 29, 2025) to regain compliance by achieving $1.00 close for ten consecutive business days.
If not compliant by deadline, Company may request second 180-day period with reverse stock split if eligible.
No immediate delisting; Company is evaluating options to address the deficiency.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Modular Medical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

June 30, 2025, Modular Medical Inc. (the “Company”) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock (“Common Stock”) for the 30 consecutive business days ending on June 27, 2025, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until December 29, 2025, in whic

View on SEC.gov

19 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Modular Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-061072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.